Inspira Reaffirms $49.5M Orders for 2026 Milestones

Inspira Technologies Oxy B.H.N. Ltd. has reaffirmed its commitment to $49.5 million in binding purchase orders, with payments and revenue recognition expected to commence in the 2026 fiscal cycle. This timing aligns with immediate regulatory sequencing and phased deployment milestones for their innovative life-support and diagnostic technologies. The company is coordinating closely with distribution partners, regulatory authorities, and institutional funding partners to manage execution, reduce risk, and ensure a phased rollout across target markets. Inspira Technologies, a medical device company with FDA-cleared products like the INSPIRA™ ART100 system and developing the HYLA™ blood sensor platform, anticipates providing further updates on execution and deployment milestones. The company is subject to forward-looking statements and risks detailed in its Form 20-F filing.